46th week of 2012 patent applcation highlights part 37 |
Patent application number | Title | Published |
20120288494 | Anti-IL-12/IL-23 antibodies and uses thereof - The present invention provides antibodies, and antigen-binding portions thereof, that bind to epitopes comprising at least one amino acid residues from residues 1-197 of the p40 subunit of IL-12 and/or IL-23. The invention further provides nucleic acids encoding the antibodies, compositions, vectors and host cells comprising the antibodies, and methods of making and using the same. | 2012-11-15 |
20120288495 | THERAPEUTIC COMPOSITIONS AND METHODS - Methods relating to treating conditions that do not respond well to EGF-r antagonist therapies are disclosed. Generally, the methods include administering to a subject a composition that includes a β-glucan and, as either a second composition or a second component of the composition, either antibody that binds to at least one antigen specific to the KRAS-mutated cells and/or an EGF-r antagonist. | 2012-11-15 |
20120288496 | Notch-Binding Agents and Antagonists and Methods of Use Thereof - The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth. | 2012-11-15 |
20120288497 | COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLT1 ANTAGONIST FOR TREATING CANCER - The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists. | 2012-11-15 |
20120288498 | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER - The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells. | 2012-11-15 |
20120288499 | METHODS FOR DIAGNOSIS AND TREATMENT OF CUTANEOUS T CELL LYMPHOMAS - The present invention relates to a method for diagnosing a cutaneous T cell lymphoma (CTCL) in a patient, detecting the abnormal expression of NKp46 receptor on malignant T cells and to a kit for diagnosing a CTCL in a patient, said kit comprising an antibody capable of detecting NKp46 receptor and an antibody capable of detecting T cells. Furthermore, the invention refers to an anti-NKp46 antibody for use in the treatment of CTCL and a pharmaceutical composition for the treatment of CTCL comprising said anti-NKp46 antibody. | 2012-11-15 |
20120288500 | HUMAN MONOCLONAL ANTIBODIES TO BTLA AND METHODS OF USE - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies. | 2012-11-15 |
20120288501 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE - New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer. | 2012-11-15 |
20120288502 | COMPOSITIONS AND METHODS FOR IMPROVING POTENCY AND BREADTH OF HIV ANTIBODIES - Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) antibodies having improved potency and breadth. | 2012-11-15 |
20120288503 | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN THE PROCESS OF BONE REMODELING - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes. | 2012-11-15 |
20120288504 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis or hypercoagulation in patients having, or at risk of developing, diseases associated with abnormal blood coagulation or fibrinolysis and/or patients which are at increased risk or are being treated by a regimen that renders the patient at increased susceptibility to hypercoagulation or thrombosis such as patients who have previously had a stroke or heart attack or persons on a treatment regimen with a drug or chemotherapy and/or radiation that is associated with increased risk of thrombosis or hypercoagulation. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al. | 2012-11-15 |
20120288505 | GENE DELIVERY - The present invention relates to a method of delivery of a therapeutic agent to a target cell, the method comprising targeting particles comprising the therapeutic agent to the cell using magnetic means to apply a magnetic force to said particles so as to tend to move said particles towards said magnetic means and at the same time moving said magnetic means. | 2012-11-15 |
20120288506 | C-KIT ANTIBODIES AND USES THEREOF - This invention is directed to antibodies that specifically bind to an extracellular domain of human c-Kit, pharmaceutical compositions comprising these antibodies, and their use in treating cancer. | 2012-11-15 |
20120288507 | WISE BINDING AGENTS AND EPITOPES - The present invention relates to binding agents for WISE, and includes methods for their manufacture and use. | 2012-11-15 |
20120288508 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 2012-11-15 |
20120288509 | ANALYSIS OF METHYLATED NUCLEIC ACID - The present invention provides a method for analysis methylation patterns in DNA and identifying aberrantly methylated genes in disease tissue. The invention also provides a method of identifying novel targets for therapeutic intervention and disease markers. Novel cancer targets are provided. | 2012-11-15 |
20120288510 | HUMAN ANTIBODIES AGAINST HEPATITIS C VIRUS (HCV) AND USES THEREOF - Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2012-11-15 |
20120288511 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon (SEQ ID NO: 2) that exhibit activity at the glucagon receptor, activity at the GLP-I receptor, or activity at each of the glucagon receptor and the GLP-I receptor. In some embodiments, the glucagon analog exhibits at least 100% or more of the activity of native glucagon at the glucagon receptor and/or at least 100% or more of the activity of native GLP-I at the GLP-I receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is within 50-fold or less than the EC50 at the glucagon receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is two- to ten-fold greater than the EC50 at the glucagon receptor. Related conjugates, dimers and multimers, and pharmaceutical compositions, and uses thereof, are further provided. | 2012-11-15 |
20120288512 | Anti-CD70 Antibody-Drug Conjugates and Their Use for the Treatment of Cancer and Immune Disorders - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions. | 2012-11-15 |
20120288513 | Means for the inhibition of anti-beta1-adrenergic receptor antibodies - Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition. | 2012-11-15 |
20120288514 | PEPTIDE VACCINES FOR CANCERS EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES - The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines. | 2012-11-15 |
20120288515 | SYNTHETIC LONG PEPTIDE (SLP)-BASED VACCINES - Synthetic long peptides and an adjuvant are formulated together and administered to a subject in order to raise an immune response. In certain embodiments, the adjuvant is GLA. | 2012-11-15 |
20120288516 | Markers of XMRV Infection And Uses Thereof - The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. Additionally, the invention relates to specific XMRV antigens capable of inducing an immunogenic response as well as XMRV-related nucleic acids having significant diagnostic, screening, and therapeutic utilities. | 2012-11-15 |
20120288517 | Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof - Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of | 2012-11-15 |
20120288518 | Chemical Reagents for the Activation of Polysaccharides in the Preparation of Conjugate Vaccines - This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable. | 2012-11-15 |
20120288519 | METHOD FOR PRODUCING BETA-CAROTENE RICH DUNALIELLA POWDER - In a step of producing a powder product of the alga belonging to the genus | 2012-11-15 |
20120288520 | Recombinant Flavivirus Vaccines - The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations. | 2012-11-15 |
20120288521 | MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS - Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided. | 2012-11-15 |
20120288522 | Novel Pneumovirus Compositions and Methods For Using the Same - Provided are newly identified | 2012-11-15 |
20120288523 | ADMINISTRATION ROUTE FOR A COMPOSITION TO PROTECT AN ANIMAL AGAINST RHODOCOCCUS EQUI - The present invention pertains to the use of | 2012-11-15 |
20120288524 | LEISHMANIA-BASED CARRIER FOR VACCINE DELIVERY - The present invention provides a composition for delivering a protein vaccination candidate to a mammalian subject having a | 2012-11-15 |
20120288525 | PHARMACEUTICAL COMPOSITIONS COMPRISING ATTENUATED PLASMODIUM SPOROZOITES AND GLYCOLIPID ADJUVANTS - Disclosed herein are pharmaceutical compositions comprising | 2012-11-15 |
20120288526 | DNA SEQUENCE AND PREPARATION OF GRASS POLLEN ALLERGEN PHL P4 BY RECOMBINANT METHODS - The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies. | 2012-11-15 |
20120288527 | ANTIALLERGIC AGENT - An agent having antiallergic effects is provided, which is easily produced and ingested. A solvent extract of green soybean is used as an antiallergic agent. A solvent extract of green soybean having the effect of suppressing IgE production and the effect of shifting the Th1-Th2 balance to the Th1 side is useful as an antiallergic agent. | 2012-11-15 |
20120288528 | MONO-AND DISACCHARIDE DERIVATIVES - The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for, inter alia, medical, pharmaceutical, cosmetic and food applications. | 2012-11-15 |
20120288529 | PHARMACEUTICAL EXCIPIENT, METHOD FOR ITS PREPARATION AND USE THEREOF - The present invention relates to a pharmaceutical excipient comprising a mixture of sugar alcohol and chitin and/or chitin derivatives, a method for its preparation and use thereof. | 2012-11-15 |
20120288530 | TISSUE SEALANTS FROM PLASMA DERIVED PROTEINS - The present invention is directed in one embodiment to a tissue adhesive or sealant composition comprising an electrophilic group containing cross-linking compound having a linker moiety of a diglycolic acid, a water soluble core moiety and an electrophilic group that is covalently bonded to the diglycolic acid linker moiety and a nucleophilic group containing protein. In other embodiments, the present invention is directed to a delivery device or a medical device on which the composition has been applied or incorporated therein. The present invention is also directed to a method for sealing tissue using the tissue adhesive or sealant composition. | 2012-11-15 |
20120288531 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF FERRIC IRON COMPOUNDS, AND METHODS OF USE THEREOF - The pharmaceutical compositions described comprise a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer for oral delivery. Some pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer (e.g. a salt of a medium chain fatty acid) and a lipophilic medium. The pharmaceutical compositions may be enteric-coated. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. The methods of treatment described herein increase the level of iron in the bloodstream of a subject by administering to the subject an effective amount of an oral composition of a ferric iron compound. | 2012-11-15 |
20120288532 | MULTI-LAYERED, MULTIPLE UNIT PHARMACEUTICAL COMPOSITIONS - The invention relates to pharmaceutical compositions comprising multilayered multiple units and processes for the preparation thereof. | 2012-11-15 |
20120288533 | PROTEIN-POLYSACCHARIDE CONJUGATES AND USE FOR ENCAPSULATING NUTRACEUTICALS FOR CLEAR BEVERAGE APPLICATIONS - The present invention provides protein (or peptide)-polysaccharide (or oligosaccharide) conjugates (PPC) as nanocapsular vehicles for nanoencapsulation of biologically active compounds, particularly nutraceuticals. The PPCs efficiently protect both hydrophobic (i.e., water insoluble) and hydrophilic (i.e., water soluble) nutraceuticals, to provide a composition which, when added to a beverage, disperses so as to provide a clear or transparent solution. In some embodiments, the PPCs are Maillard reaction based PPCs. Advantageously, the conjugates of the present invention protect the nutraceuticals from degradation, both during shelf life and upon gastric digestion. | 2012-11-15 |
20120288534 | Corticosteroids for the Treatment of Joint Pain - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 2012-11-15 |
20120288535 | RARE EARTH NANOPARTICLES - This document provides methods and materials related to rare earth particles such as rare earth nanorods (e.g., inorganic lanthanide hydroxide nanorods). For example, rare earth (e.g., lanthanide) particles such as europium hydroxide nanorods, methods and materials for making rare earth particles (e.g., europium hydroxide nanorods), and methods and materials for using rare earth particles (e.g., europium hydroxide nanorods) as an imaging agent and/or to promote angiogenesis are provided. | 2012-11-15 |
20120288536 | Stabilized Stat3 Decoy Oligonucleotides And Uses Therefor - The present invention is based, at least in part, on novel, unimolecular STAT3 oligonucleotide decoys exhibiting increased in vivo stability as compared to previously known decoys which are effective in inhibiting STAT3 when administered systemically. The invention is also based on pharmaceutical compositions comprising these unimolecular decoys, and methods for using these decoys in the treatment of cancer. | 2012-11-15 |
20120288537 | ACTIVE SELF-HEALING BIOMATERIAL SYSTEM - Methods and compositions are provided that load and encapsulate an agent, such as a protein, in a porous self-healing polymer. A delivery system includes a porous self-healing polymer, an ionic affinity trap within the pores of the self-healing polymer, and an agent associated with the ionic affinity trap. Methods of encapsulating an agent in a polymer include providing a porous self-healing polymer comprising an ionic affinity trap within the pores. The polymer is incubated with an agent having an affinity for the ionic affinity trap. At least a portion of the pores in the polymer are then healed. Active encapsulation of macromolecules at low concentrations may be achieved due to affinity of the agent for the ionic affinity trap within the pores. | 2012-11-15 |
20120288538 | VACCINE AGAINST NEOPLASTIC OR CANCEROUS LESIONS CAUSED BY HUMAN PAPILLOMA VIRUS (HPV), PROCEDURES, USES AND METHODS - Vaccine against neoplastic or cancerous lesions caused by human papillomavirus (HPV), which comprises E7 peptide spherical particles and, as an option, an adjuvant, where spherical particles may be oligomeric. The oligomeric spherical particles may have a diameter in the vicinity of 50 nm and a molecular weight in the vicinity of 700 kDa. The vaccine may be helpful to prevent or treat human papillomavirus (HPV)-related lesions or do both things at the same time. | 2012-11-15 |
20120288539 | PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES - The present invention relates to a pharmaceutical composition of oligopeptides, preferably cyclic oligopeptides, said composition further comprising one or more lipophilic and/or amphiphilic compounds, in the presence or absence of water as the main ingredients, the use of the lipophilic and/or amphiphilic compounds for making pharmaceutical compositions of said oligopeptides, and methods of making said pharmaceutical composition. | 2012-11-15 |
20120288540 | NIOSOMES, FREEZE-DRIED POWDER THEREOF AND THEIR USE IN TREATMENT - The present invention relates to a vesicular structure formed of a mixture of a non-ionic surfactant and cholesterol, characterised in that it is freeze-dried in the presence of a cryoprotectant, to a method for the preparation and to the use thereof. | 2012-11-15 |
20120288541 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 2012-11-15 |
20120288542 | SOLID PHARMACEUTICAL DISPERSIONS WITH ENHANCED BIOAVAILABILITY - Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment. | 2012-11-15 |
20120288543 | Wet Granulation Using A Water Sequestering Agent - Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process. | 2012-11-15 |
20120288544 | NOVEL RETIGABINE COMPOSITION - The present invention relates to an oral dosage form comprising N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ethyl ester (retigabine) or a pharmaceutically acceptable salt or solvate thereof, to a process for preparing such a dosage form and to the use of such a dosage form in medicine. | 2012-11-15 |
20120288545 | Compositions for Forming Films Having a Desired Degree of Obscuration and Methods of Making and Using the Same - Compositions suitable for use as skin care products (e.g., skin cream) are disclosed. Methods of making and using compositions suitable for use as skin care products are also disclosed. | 2012-11-15 |
20120288546 | Compositions for Forming Films Having a Desired Degree of Obscuration and Methods of Making and Using the Same - Compositions suitable for use as cosmetic products (e.g., skin cream) are disclosed. Methods of making and using compositions suitable for use as cosmetic products are also disclosed. | 2012-11-15 |
20120288547 | STABILIZATION OF ZINC OXIDE FILM IN ORAL COMPOSITIONS - An oral care composition and method are described in which the composition includes a film or a plurality of film fragments entrained in a carrier. The film or plurality of film fragments comprises zinc oxide. The composition and methods provide benefits including increased stability and shelf-life ensuring the delivery and bioavailability of zinc oxide. | 2012-11-15 |
20120288548 | ORAL CARE FORMULATIONS FOR MALODOR CONTROL - Described herein are oral care compositions comprising an orally acceptable carrier; and a film, wherein said film comprises an odor controlling active; a mucoadhesive polymer; a release-rate modulating polymer; a polymeric base; and optionally a flavorant; and wherein said film controls release of said odor controlling active. | 2012-11-15 |
20120288549 | COSMETIC COMPOSITION CONTAINING WHITE GINSENG POWDER - The present invention relates to a cosmetic composition containing white ginseng powder. Applying a cosmetics containing white ginseng powder to the skin of a user stimulates blood circulation and exhibits superior skin scrubbing effect. | 2012-11-15 |
20120288550 | Surface Treatment Method for a Substrate Using Denatured Urushiol Derived from Toxicodendron Vernicifluum - A method of treating a surface of a substrate using modified urushiol derived from | 2012-11-15 |
20120288551 | Implantable Polymeric Device for Sustained Release of Sufentanil - Extended release of sufentanil is provided by implanting a device containing sufentanil into a mammal or human being. The device may include a solid biocompatible polymer matrix, and sufentanil may be encapsulated within the polymer matrix. The polymer matrix comprises a plurality of pores configured to allow contact between the sufentanil and a physiological fluid of a mammal into which the device is implanted to thereby release sufentanil in vivo from the device into the mammal. The devices may be used to treat opioid addiction or pain. | 2012-11-15 |
20120288552 | COMPOSITIONS AND METHODS FOR ENCAPSULATING VACCINES FOR THE ORAL VACCINATION AND BOOSTERING OF FISH AND OTHER ANIMALS - The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals. | 2012-11-15 |
20120288553 | METHOD FOR CONTROLLING TOXICITY OF METALLIC PARTICLE AND LOW-TOXICITY COMPOSITE OF METALLIC NANOPARTICLE AND INORGANIC CLAY - The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nano silicate platelets. | 2012-11-15 |
20120288554 | CANFOSFAMIDE MONOTHERAPY FOR TREATING MULTIPLE MYELOMA - Provided herein are methods for treating multiple myeloma by administering canfosfamide or a pharmaceutically acceptable salt thereof as a monotherapy, and also by administering canfosfamide or a pharmaceutically acceptable salt thereof as part of novel combination therapies further comprising one or more of bortezomib, lenalidomide, vorinostat, carfilzomib, pomalidomide, and elotuzumab. | 2012-11-15 |
20120288555 | ANTIPROLIFERATIVE COMPOSITIONS COMPRISING CURCUMIN ANALOGS AND METHODS OF PRODUCING AND USING SAME - Antiproliferative compositions that include CLEFMA, as well as liposomal compositions containing said antiproliferative compositions, are disclosed. Also disclosed are methods of making and using the antiproliferative compositions and liposomal compositions. | 2012-11-15 |
20120288556 | CERAMIDE ANIONIC LIPOSOME COMPOSITIONS - Described herein are pharmaceutical compositions according to aspects of the present invention which include one or more hydrophilic antineoplastic chemotherapeutics, such as vinca alkyloid antineoplastic chemotherapeutics, encapsulated in ceramide anionic liposomes. Methods of treatment of a subject having cancer using the pharmaceutical compositions are described, along with methods of making ceramide anionic liposomes which encapsulate one or more hydrophilic antineoplastic chemotherapeutics in the aqueous interior of the ceramide anionic liposomes. | 2012-11-15 |
20120288557 | ACOUSTICALLY SENSITIVE DRUG DELIVERY PARTICLES COMPRISING LOW CONCENTRATIONS OF PHOSPHATIDYLETHANOLAMINE - Novel acoustically sensitive drug carrying particles comprising low concentrations of phosphatidylethanolamine are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy. | 2012-11-15 |
20120288558 | METHOD FOR ADMINISTRATION OF PEGYLATED LIPOSOMAL DOXORUBICIN - An embodiment of the present invention comprises a method of treating malignancies in a subject in need of treatment comprising administering to the subject a high loading dose of a pegylated liposomal doxorubicin (PLD) in an initial cycle, followed by a reduced dose in a second cycle, wherein the second cycle reduced dose is in the range of 20% to 50%, preferably 50%, of the initial loading dose, and thereafter one or more maintenance doses in further cycles. The interval between dose cycles is in the range of about three-to-four weeks, preferably about four weeks. The initial loading dose is in the range of between the maximum tolerated dose (MTD) and the recommended dose, preferably the MTD (for instance, in the range of about 70 mg/m2 to 50 mg/m2, preferably 60 mg/m2). The one or more maintenance doses are in the range of about 40 mg/m2 to 50 mg/m2, preferably 45 mg/m2). | 2012-11-15 |
20120288559 | ORGANIC COMPOUNDS - The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator. | 2012-11-15 |
20120288560 | Methods for the Treatment of CNS-Related Conditions - The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine. | 2012-11-15 |
20120288562 | Acid Resistant Capsules - The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer. | 2012-11-15 |
20120288563 | AMORPHOUS DARUNAVIR - Described herein is pure amorphous darunavir, methods of making pure amorphous darunavir and pharmaceutical compositions containing amorphous darunavir and a pharmaceutically acceptable excipient. | 2012-11-15 |
20120288564 | Interpenetrating polymer network comprising fibrin - There is provided a method of forming a hydrogel, the method comprising: providing a mixture of a polymer comprising a cross-linkable pendant phenolic group, peroxidase, H | 2012-11-15 |
20120288566 | LIQUID PRECURSOR COMPOSITIONS AND USES THEREOF FOR A PH-DEPENDANT SUSTAINED RELEASE TREATMENT OF ORAL DISORDERS - The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of oral disorders, at least one acidic-pH sensitive polymer, at least one hydrophobic polymer, and a pharmaceutically acceptable volatile carrier, wherein a weight ratio between said at least one hydrophobic polymer and said at least one acidic-pH sensitive polymer is larger than 1. The invention also discloses formulations formed of the solidification of these compositions, and methods for treating oral disorders by applying these compositions on hard surfaces in the oral cavity or to be placed in the oral cavity. | 2012-11-15 |
20120288568 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION - Compounds that reduce serum retinol, serum RBP, and/or serum retinol-RBP levels may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies. | 2012-11-15 |
20120288569 | PARENTERAL ADMINISTRATION OF PYROPHOSPHATE FOR PREVENTION OR TREATMENT OF PHOSPHATE OR PYROPHOSPHATE DEPLETION - Phosphate depletion, a physiological condition commonly seen in certain patient populations, including alcoholics, malnourished, acutely ill patients, patients receiving parenteral nutrition, patients being re-fed after prolong fasting, and dialysis patients, requires intravenous supplementation when oral repletion is not feasible. This invention provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate, instead of phosphate, for phosphate or pyrophosphate repletion. During hemodialysis or peritoneal dialysis significant removal of phosphate and pyrophosphate occurs. Pyrophosphate depletion predisposes patients to vascular calcification. This invention further provides a method and pharmaceutical composition for therapeutic administration of pyrophosphate for phosphate or pyrophosphate repletion by addition of pyrophosphate to hemodialysis or peritoneal dialysis solutions. | 2012-11-15 |
20120288570 | HYDROGEN PEROXIDE COMPOSITIONS AND CLEANING FORMULATIONS PREPARED THEREFROM - A hydrogen peroxide composition comprises hydrogen peroxide, a stabilizer system comprising a colloidal stannate, at least one acidifying agent or a salt thereof selected from the group consisting of sulfur-containing acidifying agents, nitric acid, and mixtures and salts thereof. Optionally, the hydrogen peroxide composition comprises an organic phosphonic acid or a salt thereof, such as amino-phosphonate, and/or a free radical scavenger, such as salicylic acid. A cleaning formulation comprises the hydrogen peroxide composition, a pH adjusting agent, and optionally other additives, such as surfactants. The cleaning formulation may be made by mixing the hydrogen peroxide or a precursor thereof, water, colloidal stannate, and at least one acidifying agent, and optionally, adjusting the pH to achieve an alkaline pH. | 2012-11-15 |
20120288571 | Antimicrobial Agents and Methods of Use - The present application relates to novel antimicrobial compositions and methods of using said antimicrobial compositions for inhibiting and treating microbial growth, microbial infections, inflammatory diseases, viral diseases, cardiovascular diseases, diabetes and/or conditions that may be regulated or associated with microbial infections, such as cancer. | 2012-11-15 |
20120288572 | MULTICHAMBER CONTAINER FOR PREPARING MEDICINAL SOLUTIONS - The subject matter of the present invention is a multichamber container and a method for preparing medical fluids composed of concentrates which make a contribution toward the electrical conductivity of the solution and are additionally prepared from concentrates which do not make a contribution toward the electrical conductivity of the solution. The inventive multichamber container is characterized in that it is constructed by dividing the solution components into multiple chambers, so that following the dissolving due to breaking open of the first chamber border of a solution component, which makes a contribution toward the electrical conductivity of the medicinal solution, another chamber border of another solution component which does not make any contribution toward the electrical conductivity of the solution is broken open. | 2012-11-15 |
20120288573 | USE OF EXTRACTS FROM SALONUM GLAUCOPHYLLUM FOR TREATING BONE METABOLISM DISORDERS AND KIDNEY DISORDERS - A method is provided for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans. It comprises providing to a subject in need of that a calcium containing or calcium enriched diet combined with the administration of an efficient amount of a plant extract of | 2012-11-15 |
20120288574 | METHOD OF PREVENTING PHOTO-AGING WITH ASHWAGANDHA AND INDIAN GOOSEBERRY - A method of preventing photo-aging and its related causes includes administering a therapeutic composition comprising extracts of the plant species ashwagandha ( | 2012-11-15 |
20120288575 | CLEANSER COMPOSITIONS AND METHODS FOR USING THE SAME - The present invention is directed to anti-microbial cleanser compositions comprising linalool, hinokitiol and dipropylene glycol. The present invention further provides methods for using these compositions to maintain eyelid hygiene, to treat an ocular disorder or to clean a skin surface. The cleanser compositions of the present invention can be in the form of a foam, gel or liquid. | 2012-11-15 |
20120288576 | EFFECTS OF HYPODAPHNIS ZENKERI ON VARIOUS CARDIOVASCULAR RISK FACTORS AND METABOLIC SYNDROME - Methods of improving a variety of health related factors including, but not limited to weight, cholesterol levels, triglyceride levels and HDL levels, is provided. In one embodiment, a method of reducing body weight in an overweight subject is provided; the method comprises administering a composition containing an effective amount of | 2012-11-15 |
20120288577 | EFFECTS OF XYLOPIA AETHIOPICA ON VARIOUS CARDIOVASCULAR RISK FACTORS AND METABOLIC SYNDROME - Methods of improving a variety of health related factors including, but not limited to weight, cholesterol levels, triglyceride levels and HDL levels, is provided. In one embodiment, a method of reducing body weight in a mammal is provided; the method comprises administering a composition containing an effective amount of | 2012-11-15 |
20120288578 | HERBAL CALF STARTER COMPOSITIONS - The invention concerns a starter composition for calves with herbal supplementation which comprises extracts or parts of medicinal herbs selected from | 2012-11-15 |
20120288579 | USE OF LIGNAN COMPOUND FOR ANTI-WRINKLE TREATMENT - The present invention relates to a novel use of lignan compounds, which are isolated and purified from nutmeg or the aril of nutmeg for anti-wrinkle, and more particularly, the present invention relates to a novel use for anti-wrinkle of an extract of the nutmeg or an extract of the aril of the nutmeg, fragrin A, austobailignan 7, licarin E, and macelignan. The extracts and lignan compounds of the present invention have activities in suppressing collagen degradation enzyme-1 (MMP-1, matrix metalloprotei-nase-1) and formation of new collagen (type-1 procollagen), thereby having effect on inhibitng wrinkle caused by photoaging. Accordingly, the extracts and lignan compounds of the present invention may be useful for preventing or treating wrinkle caused by photoaging. | 2012-11-15 |
20120288580 | Hot-Runner System Including Hot-Runner Component having Diamond-Based Material - A hot-runner system ( | 2012-11-15 |
20120288581 | BELT RUN CONTROL DEVICE, IN PARTICULAR OF A FORMING AND COOLING DEVICE - The invention relates to a belt run control device of an endless belt ( | 2012-11-15 |
20120288582 | MOLD ASSEMBLY WITH INTERCHANGEABLE INSERT FOR BLOW-MOLDING - A blow-molding mold assembly comprising: a base mold cavity ∘ matrix located within the mold-holder of a molding machine, characterized in that the assembly includes an interchangeable insert located within the base mold cavity; the base mold cavity having in its left side a gliding locking means and in its right side having fixed locking means, and the interchangeable insert having in its left and right sides groves to receive the locking means corresponding to each side of the base mold cavity to avoid longitudinal movement of the interchangeable insert, the interchangeable insert having further an exterior edge to be housed in an interior recess of the base mold cavity to avoid rotational movement of the interchangeable insert. | 2012-11-15 |
20120288583 | DEVICE FOR THE PREPARATION OF PREFORMS OF CARBON FIBER-REINFORCED COMPONENTS - Disclosed is a device for preparing preforms of carbon fiber-reinforced components including a preforming mold that can be immobilized on a work bench in an electrically insulated manner, and provided with at least two electrodes in positions in which they contact opposite end areas of the preform to generate a resistive electrical circuit through the carbon fibers to activate a binder present in the preform by heating, a leak-tight elastically deformable compacting membrane capable of adapting to the outer geometry of a preform arranged on the mold, and a pneumatic connection means connected to the compacting device to force the membrane to exert a compacting force on the preform. | 2012-11-15 |
20120288584 | TOGGLE TYPE MOLD CLAMPING DEVICE - In a toggle type mold clamping device including a plurality of link units, a coupling portion of a first link coupled with a toggle driving link is provided on an outer side of an area between a coupling portion of the toggle driving link coupled with a crosshead and a center line of the first link. Furthermore, the first link has a structure in which two members arranged in parallel are coupled and integrated with each other and a space through which the toggle driving link passes is formed between the two coupled members. | 2012-11-15 |
20120288585 | Methods of Producing GH8 Xylanase Variants - The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. | 2012-11-15 |
20120288586 | PRODUCTION OF CHEESE WITH S. THERMOPHILUS - Methods and compositions for producing cheese with | 2012-11-15 |
20120288587 | Method for Preparing a Proteinaceous Vegetable Flavor Enhancer - This invention includes a method of producing hydrolyzed vegetable protein from proteinaceous vegetable material using commercial enzymes and optimally also fresh baker's yeast as source of proteases and peptidases. The invention further includes a method of solubilizing and pasteurizing proteinaceous vegetable material. | 2012-11-15 |
20120288588 | FUNCTIONAL CEREAL FORMULATION - Nutritional or functional food compositions comprise a combination of brown rice protein isolate, yellow pea protein isolate, and hemp protein isolate. The food compositions are hypoallergenic and highly bioavailable. Methods of making suitable RTD formulations are described. | 2012-11-15 |
20120288589 | METHOD AND APPARATUS FOR VITAMIN D ENHANCEMENT IN DRIED MUSHROOM POWDER - An apparatus and method for increasing Vitamin D content in dried mushroom powder irradiates the powder with one or more pulses of UV light with wavelengths in the range of about 200 to about 800 nanometers. The powder may be conveyed into the light chamber with a vibratory conveyor. The irradiated mushroom powder has a Vitamin D2 level of at least 14,000 IU/gram. | 2012-11-15 |
20120288590 | Edible Surface-Modifying Particles and Methods for Their Manufacture - Disclosed is an edible surface-modifying particle precursor composition for preparing edible surface-modifying particles that includes one or more starches resulting in a total amylose content from the starches of about 0.1% to about 20% of the total weight of the composition. The composition also includes a ground cereal in amounts of about 10% to about 40% of the total weight of the composition; and water. Disclosed also are coated food substrates bearing such edible surface-modifying particles, and methods for making food products using the edible surface-modifying particles. | 2012-11-15 |
20120288591 | FILM COATED CONFECTIONERY PRODUCT - A film-coated confectionery product is disclosed in which a confectionery base includes or more film coated layers to impart one or more flavors, sensations, textures or combinations of these characteristics to the product when the product is consumed. | 2012-11-15 |
20120288592 | MICROWAVEABLE BATTER - A microwave cookable or reheatable foodstuff coating composition comprises 55 to 80 wt % water and 20 to 45 wt % by dry weight of an ingredient mixture including:
| 2012-11-15 |
20120288593 | APPARATUS AND METHOD FOR PREPARING EGG PRODUCTS IN A MICROWAVE OVEN - An apparatus and method is disclosed for preparing liquid egg products, for example pure egg whites, whole eggs and egg products either alone or mixed with spices, vegetables or other ingredients, in a microwave oven. The container for preparing the liquid egg products is relatively inexpensive and disposable. In another embodiment of the present invention, a method is provided for preparing liquid egg products in a disposable, microwavable container in which the liquid egg product expands while cooking and partially removes the lid of the container to create a delicious meal of properly cooked, fresh egg product, that are ready for consumption. | 2012-11-15 |
20120288594 | METHOD AND PLANT FOR PACKAGING FRESH FOOD PRODUCTS, SUCH AS FRUIT AND VEGETABLES, AND FOOD PRODUCT THUS PACKAGED - A method for packaging a fresh food product, such as fruit and vegetables, provided externally with a protective peel, having at least a peeling step, in which the peel is removed from the product. After the peeling step, the method provides at least a covering step, in which at least a covering film is associated with the external surface of the product. The method also provides a molding step in which the covering film is made to adhere to the external surface of the product. | 2012-11-15 |
20120288595 | Closed Loop Adaptive Control System for Cooking Appliance - A cooking application ( | 2012-11-15 |
20120288596 | COOKING APPARATUS WITH DOWNWARD OPENING LID - Provided is a cooking/grilling apparatus, primarily for outdoor use, providing smoking and/or direct or indirect heat cooking capability, and offering the user enhanced cooking flexibility, temperature control, safety and convenience of operation. The grill apparatus is unique in that it offers a downward opening lid that rotates, such as on rollers or a pivot mechanism, to a fully open position beneath the base plate of the cooking enclosure, and reverses to an upward rotation to re-close the cooking enclosure. Moreover, the grill apparatus offers a vertically adjustable cooking grate, controlled by a continuous loop cable, moving over a set of pulleys, thereby reliably controlling the height of the cooking grate when affixed to a crank on the outer surface of the grill, wherein movement of the grate can also be locked in place. | 2012-11-15 |